Physician profile
Corey M Warner
NPI 1801998968
$5,180.95
in general payments reported to CMS, 2019-2025
28 companies · $775 in 2025
The $775 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,381 · 2020: $789 · 2021: $134 · 2022: $257 · 2023: $417 · 2024: $428 · 2025: $775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,620.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $819.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $624.91 | 2019-2025 | Jardiance |
| Allergan, INC. | $496.54 | 2019-2020 | |
| Abbvie INC. | $486.82 | 2020-2025 | Vraylar, Ubrelvy |
| Janssen Pharmaceuticals, INC | $407.60 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $396.80 | 2019-2025 | Breztri |
| Pfizer INC. | $366.97 | 2019-2025 | |
| Lilly USA, LLC | $244.06 | 2019-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $220.04 | 2019-2024 | Trelegy Ellipta, Arexvy |
| E.R. Squibb & Sons, L.L.C. | $174.01 | 2019 | |
| Novartis Pharmaceuticals Corporation | $156.35 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $123.84 | 2024-2025 | Ingrezza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.99 | 2019-2025 | Xifaxan |
| Abbott Laboratories | $87.35 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $70.92 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $53.74 | 2022 | |
| Astellas Pharma US INC | $53.25 | 2019 | |
| Exact Sciences Corporation | $44.99 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $41.44 | 2023 | |
| Eisai INC. | $32.53 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.56 | 2019 | |
| Merck Sharp & Dohme LLC | $26.91 | 2019 | |
| Amarin Pharma, INC. | $26.29 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $22.42 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.29 | 2023 | |
| Sanofi Pasteur INC. | $18.31 | 2019 | |
| Circassia INC. | $16.56 | 2020 | |
| Lundbeck LLC | $15.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corey Warner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.